Homburger houses a broad offering which often advises on cross-border merger control, financing, and patent enforcement mandates. The team notably assists Novartis, Biocorp Holding, and Catalent. Daniel Häusermann stands out due to his broad experience in equity capital markets transactions, and both public and private M&A, while Andri Hess often assists clients with patent litigation and contractual IP issues. Richard Stäuber is well-known for his vast knowledge of merger control and competition investigation issues, with a strong focus on distribution arrangements.

Legal 500 Editorial commentary

Key clients

  • Catalent
  • Novartis
  • Roche
  • ADC Therapeutics
  • Santhera
  • Biocorp
  • Addex Therapeutics
  • Sonic Healthcare
  • Sandoz
  • Eli Lilly
  • CSL
  • Illumina
  • Bristol Myers-Squibb
  • Edwards Lifesciences
  • VectivBio
  • Therachon
  • Spectris
  • Atara Biotherapeutics
  • Straumann
  • Sonova
  • Siegfried
  • Biognosys
  • BIOBank
  • Strides Pharma Science
  • Octapharma
  • Horizon Therapeutics
  • PHOENIX Pharma
  • Amedis
  • CDR-Life

Work highlights

  • Representing Catalent in Swiss merger control proceedings related to its USD 16.5 bn acquisition by Novo Holdings.
  • Advised Novartis on the divestment of Life Science Park Rhine Valley to GETEC.
  • Representing Novartis in enforcing patents against generic JADENU (deferasirox) products.

Lawyers

Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.

Practice head

The lawyer(s) leading their teams.

Daniel Häusermann, Andri Hess, Richard Stäuber